NCT06973564View on ClinicalTrials.gov

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

February 29, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

JAB-23E73

Oral administration

DRUG

JAB-23E73

Oral administration

DRUG

JAB-23E73

Oral administration

Trial Locations (4)

44195

Cleveland Clinic Foundation, Cleveland

55905

Mayo Clinic, Rochester

63110

Washington University, St Louis

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors
All Listed Sponsors
lead

Jacobio Pharmaceuticals Co., Ltd.

INDUSTRY